Abstract:The connection of two or more proteins with different binding specificities or activities can lead to unique and powerful systems with significant potential in therapeutic applications, particularly oncology. While a plethora of active bifunctional proteins have been produced by fusion, this approach is not always viable, since modification of the N- or C- terminus can compromise the proteins’ bioactivities, with complications during folding and processing often being observed. Chemical cross-linking can offer a more versatile strategy towards the synthesis of protein-protein conjugates. However, current state-of-the-art approaches are either not selective, yielding heterogeneous mixtures or require mutations with natural or unnatural amino acids, which are often associated with low expression yields and limited applicability towards all protein systems. Recently, a bis-dibromomaleimide cross-linking reagent was used to create a bispecific scFv-Fab antibody in a site-specific manner, by targeting and bridging disulfide bonds. In this work, the application of these cross-linking reagents was extended into the conjugation of proteins containing different reactive handles, as well as sterically hindered conjugation sites. Diiodo-maleimides were shown to offer the ideal properties of rapid bioconjugation and importantly, reduced hydrolysis, which was identified as a significant factor affecting the conjugation efficiency. The optimized linkers were exploited to link human serum albumin to antibody fragments (scFv and Fab) as a prospective half-life extension platform, with retention of antigen binding and robust serum stability. The linker design was also extended to incorporate a third point of attachment for another biomolecule. An anti-CEA scFv homotrimer was formed, by disulfide bridging, which was shown to infer a combination of greater antigen avidity and increased in vivo half-life. Finally, with the view to developing a Bispecific T-cell Engager (BiTE) construct that could lead to more efficient cell-killing, an anti-CEA/ anti-CD3 scFv heterotrimer of increased avidity towards CD3 antigen was developed, showing the potential of this strategy for the construction of a diverse range of bioconjugates. The last part of this thesis describes investigations towards the development of a new methodology that selectively modifies specific lysine residues, via acyl transfer from the disulfide bond of Fab antibody fragment. This approach is expected to complement disulfide bridging as a strategy for selective modification, but also be advantageous for systems where this could result in detrimental changes to the antibody structure, offering a highly promising platform for bioconjugation.

Nickel-Catalyzed Antibody Bioconjugation

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

Click‐on Antibody Fragments for Customisable Targeted Nanomedicines – Site‐specific Tetrazine and Azide Functionalisation through Non‐canonical Amino Acid incorporation

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.

An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the PtII Linker Lx for Improved Manufacturability of Antibody-Drug Conjugates

Bridged Cysteine Conjugations

Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Cysteine-Based Coupling: Challenges and Solutions

Site-specific antibody drug conjugates for cancer therapy

Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies

New Strategies for Cysteine Bioconjugation and Protein Cross-Linking

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

Antibody conjugation via one and two C-terminal selenocysteines

A Single-Step Chemoenzymatic Reaction for the Construction of Antibody-Cell Conjugates

Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase